vix.ing · top · new · best · stats

Cancer statistics, 2022

2022/01/01 by Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs +1 · 1 voice · 18,276 citations
Economics, Econometrics and Finance · Medicine · #Breast cancer #Cancer #Cancer Risks and Factors #Cancer registry #Demography #Disease #Economic and Financial Impacts of Cancer #Environmental health #Epidemiology #Epidemiology of cancer #Global Cancer Incidence and Screening #Incidence (geometry) #Internal medicine #Lung cancer #Medicine #Mortality rate #Oncology #Population #Prostate cancer #Relative survival

paper · pdf · doi:10.3322/caac.21708

published in CA A Cancer Journal for Clinicians 72(1), 7-33 (Wiley)

openalex publication_date 2022/01/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

Citations

Cited by

Discussions

Related